GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis
EPA:ALGEN - FR0004053510 - Common Stock
2.73 EUR
-0.17 (-5.86%)
Taking everything into account, ALGEN scores 5 out of 10 in our fundamental rating. ALGEN was compared to 74 industry peers in the Biotechnology industry. Both the profitability and the financial health of ALGEN get a neutral evaluation. Nothing too spectacular is happening here. ALGEN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ALGEN had positive earnings in the past year.
ALGEN had a positive operating cash flow in the past year.
In multiple years ALGEN reported negative net income over the last 5 years.
In multiple years ALGEN reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of ALGEN (3.96%) is better than 79.73% of its industry peers.
The Return On Equity of ALGEN (7.06%) is better than 79.73% of its industry peers.
ALGEN's Return On Invested Capital of 6.13% is amongst the best of the industry. ALGEN outperforms 83.78% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ALGEN is significantly below the industry average of 12.87%.
The last Return On Invested Capital (6.13%) for ALGEN is above the 3 year average (5.56%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| ROIC | 6.13% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 5.86%, ALGEN is doing good in the industry, outperforming 78.38% of the companies in the same industry.
ALGEN has a better Operating Margin (8.09%) than 79.73% of its industry peers.
ALGEN has a better Gross Margin (92.34%) than 89.19% of its industry peers.
In the last couple of years the Gross Margin of ALGEN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.09% | ||
| PM (TTM) | 5.86% | ||
| GM | 92.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
2. Health
2.1 Basic Checks
ALGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ALGEN has been reduced compared to 1 year ago.
Compared to 5 years ago, ALGEN has more shares outstanding
The debt/assets ratio for ALGEN has been reduced compared to a year ago.
2.2 Solvency
ALGEN has an Altman-Z score of 2.42. This is not the best score and indicates that ALGEN is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.42, ALGEN is in the better half of the industry, outperforming 70.27% of the companies in the same industry.
The Debt to FCF ratio of ALGEN is 1.41, which is an excellent value as it means it would take ALGEN, only 1.41 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 1.41, ALGEN belongs to the best of the industry, outperforming 93.24% of the companies in the same industry.
ALGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.26, ALGEN perfoms like the industry average, outperforming 59.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.41 | ||
| Altman-Z | 2.42 |
ROIC/WACC0.88
WACC6.96%
2.3 Liquidity
A Current Ratio of 1.92 indicates that ALGEN should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.92, ALGEN is in line with its industry, outperforming 48.65% of the companies in the same industry.
A Quick Ratio of 1.81 indicates that ALGEN should not have too much problems paying its short term obligations.
ALGEN has a Quick ratio of 1.81. This is comparable to the rest of the industry: ALGEN outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.81 |
3. Growth
3.1 Past
ALGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.41%, which is quite good.
ALGEN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.04%.
Measured over the past years, ALGEN shows a quite strong growth in Revenue. The Revenue has been growing by 18.46% on average per year.
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
3.2 Future
ALGEN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by 0.00% yearly.
ALGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.37% yearly.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 13.00 indicates a correct valuation of ALGEN.
Compared to the rest of the industry, the Price/Earnings ratio of ALGEN indicates a rather cheap valuation: ALGEN is cheaper than 90.54% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.06. ALGEN is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ALGEN is valued cheaper than 93.24% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ALGEN indicates a rather cheap valuation: ALGEN is cheaper than 94.59% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.71 | ||
| EV/EBITDA | 4.79 |
4.3 Compensation for Growth
ALGEN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%
5. Dividend
5.1 Amount
ALGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:ALGEN (9/5/2025, 7:00:00 PM)
2.73
-0.17 (-5.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners9.39%
Ins Owner ChangeN/A
Market Cap25.88M
Analysts86.67
Price Target6.02 (120.51%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13 | ||
| Fwd PE | N/A | ||
| P/S | 1.21 | ||
| P/FCF | 5.71 | ||
| P/OCF | 3.75 | ||
| P/B | 1.46 | ||
| P/tB | 2.13 | ||
| EV/EBITDA | 4.79 |
EPS(TTM)0.21
EY7.69%
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.48
FCFY17.51%
OCF(TTM)0.73
OCFY26.69%
SpS2.26
BVpS1.88
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| ROCE | 7.62% | ||
| ROIC | 6.13% | ||
| ROICexc | 7.79% | ||
| ROICexgc | 11.35% | ||
| OM | 8.09% | ||
| PM (TTM) | 5.86% | ||
| GM | 92.34% | ||
| FCFM | 21.15% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score5
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.41 | ||
| Debt/EBITDA | 0.77 | ||
| Cap/Depr | 55.06% | ||
| Cap/Sales | 11.1% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 114.18% | ||
| Profit Quality | 360.76% | ||
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.81 | ||
| Altman-Z | 2.42 |
F-Score5
WACC6.96%
ROIC/WACC0.88
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y0.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200%
EBIT Next 3Y68.69%
EBIT Next 5YN/A
FCF growth 1Y308.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1010.09%
OCF growth 3YN/A
OCF growth 5YN/A